UDENYCA® is the #1 prescribed pegfilgrastim product prefilled syringe*1
An FDA-approved biosimilar to Neulasta® (pegfilgrastim)
* As of January 2022, the pegfilgrastim prefilled syringe (PFS) marketplace includes ZIEXTENZO® (pegfilgrastim-bmez), Fulphila® (pegfilgrastim-jmdb), and Neulasta® (pegfilgrastim).
* As of January 2022, the pegfilgrastim prefilled syringe (PFS) marketplace includes ZIEXTENZO® (pegfilgrastim-bmez), Fulphila® (pegfilgrastim-jmdb), and Neulasta® (pegfilgrastim).
UDENYCA® offers cost savings, reliable manufacturing, patient support, and more.
See why UDENYCA® is the #1 prescribed pegfilgrastim prefilled syringe (PFS) in the video below.


of biosimilars


treatment





Biosimilars Offer Choice Without Compromise
Biosimilars are safe, effective, and affordable alternatives to existing brand biologics. At Coherus BioSciences, we’re committed to ensuring patient access to biologics through high-quality, high-value biosimilars.
LEARN MORE 

Comprehensive patient support services
Coherus COMPLETE™ provides a suite of patient support services, programs, and industry-leading electronic services designed to assist with patient access.
LEARN MORE 
Out-of-pocket (OOP) cost for each UDENYCA® dose*
Note: The Coherus COMPLETE™ Co-Pay Assistance Program covers ONLY the cost of UDENYCA® and does not cover any administration or office visit costs.
* As of January 2021, the pegfilgrastim prefilled syringe (PFS) marketplace includes ZIEXTENZO® (pegfilgrastim-bmez), Fulphila® (pegfilgrastim-jmdb), and Neulasta® (pegfilgrastim).
† Based on wholesale acquisition cost (WAC). WAC does not necessarily reflect actual prices paid by consumers, pharmacies, or third-party payers. UDENYCA® WAC of $4175 per prefilled syringe vs Neulasta® WAC of $6231 per prefilled syringe.
References: 1. IQVIA Monthly National Sales Perspective Data. 2020. 2. First Databank, Inc. Pricing Compendia. 3. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2019. 4. Neulasta® (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2020. 5. Data on file. Coherus BioSciences, Inc.; 2021.